id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2010-E-0662-0001,FDA,FDA-2010-E-0662,Aventis Pharma S.A. - Patent Term Extension Application,Other,APP-Application,2010-12-30T05:00:00Z,2010,12,2010-12-30T05:00:00Z,,2013-07-27T23:41:23Z,,0,0,0900006480bc2a98
FDA-2010-N-0118-0005,FDA,FDA-2010-N-0118,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Imported Food under 2002 Public Health Security and Bioterrorism Preparedness and Response Act of 2002",Notice,N-Notice,2010-12-30T05:00:00Z,2010,12,2010-12-30T05:00:00Z,,2010-12-30T14:44:54Z,2010-32946,0,0,0900006480bc26ef
FDA-1997-N-0020-0047,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:20:38Z,,0,0,0900006480bc1cde
FDA-2010-N-0356-0004,FDA,FDA-2010-N-0356,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Designated New Animal Drugs for Minor Use and Minor Species",Notice,N-Notice,2010-12-30T05:00:00Z,2010,12,2010-12-30T05:00:00Z,,2010-12-30T14:39:28Z,2010-32948,0,0,0900006480bc26eb
FDA-2010-E-0656-0001,FDA,FDA-2010-E-0656,Amgen Inc. - Patent Term Extension Application,Other,APP-Application,2010-12-30T05:00:00Z,2010,12,2010-12-30T05:00:00Z,,2013-08-11T04:43:36Z,,0,0,0900006480bc285b
FDA-1997-N-0020-0034,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:20:15Z,,0,0,0900006480bc0e46
FDA-1997-N-0020-0022,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:19:54Z,,0,0,0900006480bc0dca
FDA-1997-N-0020-0038,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:20:22Z,,0,0,0900006480bc1ae6
FDA-2010-E-0656-0003,FDA,FDA-2010-E-0656,U.S. Patent and Trademark Office to FDA - Letter,Other,LET-Letter,2010-12-30T05:00:00Z,2010,12,2010-12-30T05:00:00Z,,2010-12-30T16:57:57Z,,0,0,0900006480bc28a7
FDA-2010-E-0659-0001,FDA,FDA-2010-E-0659,Amgen Inc. - Patent Term Extension Application,Other,APP-Application,2010-12-30T05:00:00Z,2010,12,2010-12-30T05:00:00Z,,2013-07-27T23:41:21Z,,0,0,0900006480bc28b0
FDA-1997-N-0020-0024,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:19:58Z,,0,0,0900006480bc0dcc
FDA-1997-N-0020-0025,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:19:59Z,,0,0,0900006480bc0dd0
FDA-1997-N-0020-0029,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:20:07Z,,0,0,0900006480bc0e41
FDA-1997-N-0020-0035,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:20:17Z,,0,0,0900006480bc0e47
FDA-2010-E-0662-0002,FDA,FDA-2010-E-0662,U.S. Patent and Trademark Office to FDA - Letter,Other,LET-Letter,2010-12-30T05:00:00Z,2010,12,2010-12-30T05:00:00Z,,2013-08-11T01:39:02Z,,0,0,0900006480bc2a9a
FDA-2010-E-0661-0002,FDA,FDA-2010-E-0661,U.S. Patent and Trademark Office to FDA - Letter,Other,LET-Letter,2010-12-30T05:00:00Z,2010,12,2010-12-30T05:00:00Z,,2013-07-27T23:41:23Z,,0,0,0900006480bc2a28
FDA-1997-N-0020-0023,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:19:56Z,,0,0,0900006480bc0dcb
FDA-1997-N-0020-0044,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:20:33Z,,0,0,0900006480bc1cd8
FDA-2010-E-0656-0002,FDA,FDA-2010-E-0656,U.S. Patent and Trademark Office to FDA - Letter,Other,LET-Letter,2010-12-30T05:00:00Z,2010,12,2010-12-30T05:00:00Z,,2013-07-27T23:41:21Z,,0,0,0900006480bc285c
FDA-1997-N-0020-0030,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:20:08Z,,0,0,0900006480bc0e42
FDA-1997-N-0020-0039,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:20:24Z,,0,0,0900006480bc1ae7
FDA-1997-N-0020-0043,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:20:31Z,,0,0,0900006480bc1cd6
FDA-1997-N-0020-0028,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:20:05Z,,0,0,0900006480bc0e40
FDA-1997-N-0020-0046,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:20:37Z,,0,0,0900006480bc1cda
FDA-1997-N-0020-0049,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:20:42Z,,0,0,0900006480bc210a
FDA-1997-N-0020-0036,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:20:19Z,,0,0,0900006480bc0e6a
FDA-2010-E-0657-0002,FDA,FDA-2010-E-0657,U.S. Patent and Trademark Office to FDA - Letter,Other,LET-Letter,2010-12-30T05:00:00Z,2010,12,2010-12-30T05:00:00Z,,2010-12-30T18:00:32Z,,0,0,0900006480bc28ab
FDA-2010-E-0657-0001,FDA,FDA-2010-E-0657,Amgen Inc. - Patent Term Extension Application,Other,APP-Application,2010-12-30T05:00:00Z,2010,12,2010-12-30T05:00:00Z,,2013-08-11T01:39:02Z,,0,0,0900006480bc28a9
FDA-1997-N-0020-0048,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:20:40Z,,0,0,0900006480bc2109
FDA-1997-N-0020-0027,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:20:03Z,,0,0,0900006480bc0e3f
FDA-1997-N-0020-0037,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:20:21Z,,0,0,0900006480bc0e6b
FDA-1997-N-0020-0026,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:20:01Z,,0,0,0900006480bc0e3e
FDA-2010-E-0657-0003,FDA,FDA-2010-E-0657,U.S. Patent and Trademark Office to FDA - Letter,Other,LET-Letter,2010-12-30T05:00:00Z,2010,12,2010-12-30T05:00:00Z,,2010-12-30T18:00:33Z,,0,0,0900006480bc28ae
FDA-2010-E-0659-0003,FDA,FDA-2010-E-0659,U.S. Patent and Trademark Office to FDA - Letter,Other,LET-Letter,2010-12-30T05:00:00Z,2010,12,2010-12-30T05:00:00Z,,2013-07-27T23:41:22Z,,0,0,0900006480bc29ce
FDA-2010-E-0663-0002,FDA,FDA-2010-E-0663,U.S. Patent and Trademark Office to FDA - Letter,Other,LET-Letter,2010-12-30T05:00:00Z,2010,12,2010-12-30T05:00:00Z,,2013-08-11T04:43:37Z,,0,0,0900006480bc2a9e
FDA-2010-E-0663-0001,FDA,FDA-2010-E-0663,"Danek, et al. - Patent Term Extension Application",Other,APP-Application,2010-12-30T05:00:00Z,2010,12,2010-12-30T05:00:00Z,,2013-07-27T23:41:23Z,,0,0,0900006480bc2a9c
FDA-1997-N-0020-0042,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:20:30Z,,0,0,0900006480bc1b4e
FDA-1997-N-0020-0031,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:20:10Z,,0,0,0900006480bc0e43
FDA-1997-N-0020-0032,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:20:12Z,,0,0,0900006480bc0e44
FDA-1997-N-0020-0040,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:20:26Z,,0,0,0900006480bc1b4a
FDA-1997-N-0020-0045,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:20:35Z,,0,0,0900006480bc1cd9
FDA-1997-N-0020-0041,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:20:28Z,,0,0,0900006480bc1b4d
FDA-1997-N-0020-0033,FDA,FDA-1997-N-0020,Background Material,Supporting & Related Material,BKG-Background Material,2010-12-30T05:00:00Z,2010,12,,,2010-12-30T13:20:14Z,,0,0,0900006480bc0e45
FDA-2010-E-0659-0002,FDA,FDA-2010-E-0659,U.S. Patent and Trademark Office to FDA - Letter,Other,LET-Letter,2010-12-30T05:00:00Z,2010,12,2010-12-30T05:00:00Z,,2013-07-27T23:41:22Z,,0,0,0900006480bc29cc
FDA-2010-E-0661-0001,FDA,FDA-2010-E-0661,Aventis Pharma S.A. - Patent Term Extension Application,Other,APP-Application,2010-12-30T05:00:00Z,2010,12,2010-12-30T05:00:00Z,,2013-07-27T23:41:23Z,,0,0,0900006480bc2a24
FDA-2010-E-0653-0001,FDA,FDA-2010-E-0653,"Gilead Sciences, Inc. - Patent Term Extension Application",Other,APP-Application,2010-12-29T05:00:00Z,2010,12,2010-12-29T05:00:00Z,,2013-07-27T23:41:14Z,,0,0,0900006480bc1ee3
FDA-2008-E-0266-0008,FDA,FDA-2008-E-0266,U.S. Patent and Trademark Office to Johnson & Johnson - Notice of Final Determination Letter,Other,LET-Letter,2010-12-29T05:00:00Z,2010,12,2010-12-29T05:00:00Z,,2013-07-27T23:41:14Z,,0,0,0900006480bc1ecf
FDA-1978-N-0021-0034,FDA,FDA-1978-N-0021,Attachment 2 - FDA Alert (12/11/2008)  [FDA-1978-N-0021-0032],Supporting & Related Material,LET-Letter (Supporting and Related Material),2010-12-29T05:00:00Z,2010,12,,,2010-12-29T19:21:54Z,,0,0,0900006480bc2184
FDA-2010-E-0653-0002,FDA,FDA-2010-E-0653,U.S. Patent and Trademark Office to FDA - Letter,Other,LET-Letter,2010-12-29T05:00:00Z,2010,12,2010-12-29T05:00:00Z,,2013-07-27T23:41:14Z,,0,0,0900006480bc1ee5
FDA-2010-N-0001-0163,FDA,FDA-2010-N-0001,Meetings: Pulmonary-Allergy Drugs Advisory Committee,Notice,NM-Notice of Meeting,2010-12-29T05:00:00Z,2010,12,2010-12-29T05:00:00Z,,2010-12-29T15:23:00Z,2010-32735,0,0,0900006480bc1b9a
FDA-1997-N-0020-0018,FDA,FDA-1997-N-0020,"Reference 3 - Memorandum for the Heads of Executive Departments and Agencies, June 1, 1998, Substances Generally Recognized as Safe; Reopening of the Comment Period re FDA-1997-N-0020-0013",Supporting & Related Material,Reference (internal unless indicated),2010-12-29T05:00:00Z,2010,12,,,2011-10-26T21:47:06Z,,0,0,0900006480bc13ac
FDA-1978-N-0021-0035,FDA,FDA-1978-N-0021,Attachment 3 - FDA Alert (5/2006)  [FDA-1978-N-0021-0032],Supporting & Related Material,BKG-Background Material,2010-12-29T05:00:00Z,2010,12,,,2010-12-29T19:30:50Z,,0,0,0900006480bc2187
FDA-2010-E-0654-0002,FDA,FDA-2010-E-0654,U.S Patent and Trademark Office to FDA - Letter,Other,LET-Letter,2010-12-29T05:00:00Z,2010,12,2010-12-29T05:00:00Z,,2013-07-27T23:41:17Z,,0,0,0900006480bc2342
FDA-2010-E-0655-0002,FDA,FDA-2010-E-0655,U.S Patent and Trademark Office to FDA - Letter,Other,LET-Letter,2010-12-29T05:00:00Z,2010,12,2010-12-29T05:00:00Z,,2013-07-27T23:41:17Z,,0,0,0900006480bc2344
FDA-1997-N-0020-0015,FDA,FDA-1997-N-0020,Index of Background Material re Substances Generally Recognized as Safe; Reopening of the Comment Period re FDA-1997-N-0020-0013,Supporting & Related Material,Reference (internal unless indicated),2010-12-29T05:00:00Z,2010,12,,,2011-10-26T21:42:44Z,,0,0,0900006480bc0bea
FDA-1997-N-0020-0014,FDA,FDA-1997-N-0020,"FDA/CFSAN to the Division of Dockets Management, February 6, 2006",Other,Memorandum,2010-12-29T05:00:00Z,2010,12,2010-12-29T05:00:00Z,,2011-10-26T21:51:50Z,,0,0,0900006480bc0beb
FDA-1997-N-0020-0021,FDA,FDA-1997-N-0020,"Reference 6 - Guidance for Industry: Frequently Asked Questions About GRAS, December 2004, Substances Generally Recognized as Safe; Reopening of the Comment Period re FDA-1997-N-0020-0013",Supporting & Related Material,Reference (internal unless indicated),2010-12-29T05:00:00Z,2010,12,,,2011-10-26T21:48:28Z,,0,0,0900006480bc13da
FDA-1978-N-0021-0033,FDA,FDA-1978-N-0021,"Attachment 1 - Letter to Peter S. Reichertz, Esq [FDA-1978-N-0021-0032]",Supporting & Related Material,LET-Letter (Supporting and Related Material),2010-12-29T05:00:00Z,2010,12,,,2010-12-29T19:16:08Z,,0,0,0900006480bc2182
FDA-1997-N-0020-0020,FDA,FDA-1997-N-0020,"Reference 5 - Nanotechnology Task Force Report 2007, Substances Generally Recognized as Safe; Reopening of the Comment Period re FDA-1997-N-0020-0013",Supporting & Related Material,Reference (internal unless indicated),2010-12-29T05:00:00Z,2010,12,,,2011-10-26T21:48:05Z,,0,0,0900006480bc13d9
FDA-1997-N-0020-0016,FDA,FDA-1997-N-0020,"Reference 1 - Experience With GRAS Notices Under the 1997 Proposed Rule, November 4, 2010, Substances Generally Recognized as Safe; Reopening of the Comment Period re FDA-1997-N-0020-0013",Supporting & Related Material,Reference (internal unless indicated),2010-12-29T05:00:00Z,2010,12,,,2011-10-26T21:45:51Z,,0,0,0900006480bc0bec
FDA-1978-N-0021-0032,FDA,FDA-1978-N-0021,"Letter from FDA/CDER to Peter S. Reichertz, Esq. and Christopher A. Brown, Esq.",Other,LET-Letter,2010-12-29T05:00:00Z,2010,12,2010-12-29T05:00:00Z,,2016-09-13T15:18:53Z,,0,0,0900006480bc2181
FDA-2010-E-0654-0001,FDA,FDA-2010-E-0654,"Gilead Sciences, Inc. - Patent Term Extension Application",Other,APP-Application,2010-12-29T05:00:00Z,2010,12,2010-12-29T05:00:00Z,,2013-07-27T23:41:17Z,,0,0,0900006480bc225b
FDA-2010-E-0655-0001,FDA,FDA-2010-E-0655,"Gilead Sciences, Inc. - Patent Term Extension Application",Other,APP-Application,2010-12-29T05:00:00Z,2010,12,2010-12-29T05:00:00Z,,2013-08-11T03:12:28Z,,0,0,0900006480bc2343
FDA-1978-N-0021-0036,FDA,FDA-1978-N-0021,Attachment 4 - Science Backgrounder: Safethy of Sodium Phosphates Oral Solution  [FDA-1978-N-0021-0032],Supporting & Related Material,LET-Letter (Supporting and Related Material),2010-12-29T05:00:00Z,2010,12,,,2010-12-29T19:35:46Z,,0,0,0900006480bc226a
FDA-2010-N-0640-0001,FDA,FDA-2010-N-0640,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Data To Support Food and Nutrition Product Communications, as Used by Food and Drug Administration",Notice,N-Notice,2010-12-29T05:00:00Z,2010,12,2010-12-29T05:00:00Z,2011-03-01T04:59:59Z,2010-12-29T15:29:12Z,2010-32739,0,0,0900006480bc1bc0
FDA-1997-N-0020-0019,FDA,FDA-1997-N-0020,"Reference 4 - Notification for New Use of a Food Contact Substance, FDA Form No. 3480, Substances Generally Recognized as Safe; Reopening of the Comment Period re FDA-1997-N-0020-0013",Supporting & Related Material,Reference (internal unless indicated),2010-12-29T05:00:00Z,2010,12,,,2011-10-26T21:47:37Z,,0,0,0900006480bc13ad
FDA-1997-N-0020-0017,FDA,FDA-1997-N-0020,"Reference 2 - GAO, FDA Should Strengthen Its Oversight of Food Ingredients Determinationed to Be Generally Recognized as Safe (GRAS) Report No. GAO-10-246, February 2010, Substances Generally Recognized as Safe; Reopening of the Comment Period re FDA-1997-N-0020-0013",Supporting & Related Material,Reference (internal unless indicated),2010-12-29T05:00:00Z,2010,12,,,2011-10-26T21:46:25Z,,0,0,0900006480bc13ab
FDA-2010-N-0511-0003,FDA,FDA-2010-N-0511,FDA/DDM Letter to Division of Wyeth Holdings - Letter,Other,LET-Letter,2010-12-29T05:00:00Z,2010,12,2010-12-29T05:00:00Z,,2010-12-29T14:34:06Z,,0,0,0900006480bc1b46
FDA-2010-N-0198-0003,FDA,FDA-2010-N-0198,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Premarket Notification",Notice,N-Notice,2010-12-28T05:00:00Z,2010,12,2010-12-28T05:00:00Z,,2010-12-28T16:44:38Z,2010-32508,0,0,0900006480bc11ca
FDA-2010-P-0326-0003,FDA,FDA-2010-P-0326,"Determination that Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness: TRANDATE (Labetalol Hydrochloride) Tablets, 300 Milligrams and 400 Milligrams",Notice,N-Notice,2010-12-28T05:00:00Z,2010,12,2010-12-28T05:00:00Z,,2010-12-28T16:37:57Z,2010-32507,0,0,0900006480bc11ac
FDA-2008-E-0261-0008,FDA,FDA-2008-E-0261,U.S. Patent and Trademark Office to Nixon Peabody LLP - Notice of Final Determination,Other,LET-Letter,2010-12-28T05:00:00Z,2010,12,2010-12-28T05:00:00Z,,2013-07-27T23:40:43Z,,0,0,0900006480bc0e70
FDA-2010-N-0002-0088,FDA,FDA-2010-N-0002,New Animal Drugs: Deslorelin,Rule,NFR-Notice of Final Rule,2010-12-28T05:00:00Z,2010,12,2010-12-28T05:00:00Z,,2010-12-28T15:43:43Z,2010-32554,0,0,0900006480bc0c09
FDA-2009-E-0014-0007,FDA,FDA-2009-E-0014,U.S. Patent & Trademark Office to Abbott Diabetes Care Inc. - Letter with enclosure,Other,LET-Letter,2010-12-28T05:00:00Z,2010,12,2010-12-28T05:00:00Z,,2013-07-27T23:40:43Z,,0,0,0900006480bc0e15
FDA-2010-N-0001-0161,FDA,FDA-2010-N-0001,Meetings: Anesthetic and Life Support Drugs Advisory Committee,Notice,NM-Notice of Meeting,2010-12-28T05:00:00Z,2010,12,2010-12-28T05:00:00Z,,2010-12-28T16:11:53Z,2010-32591,0,0,0900006480bc0c47
FDA-2008-E-0258-0008,FDA,FDA-2008-E-0258,U.S. Patent and Trademark Office to Nixon Peabody LLP - Notice of Final Determination,Other,LET-Letter,2010-12-28T05:00:00Z,2010,12,2010-12-28T05:00:00Z,,2013-07-27T23:40:43Z,,0,0,0900006480bc0e6e
FDA-2008-E-0260-0008,FDA,FDA-2008-E-0260,U.S. Patent and Trademark Office to Nixon Peabody LLP - Notice of Final Determination,Other,LET-Letter,2010-12-28T05:00:00Z,2010,12,2010-12-28T05:00:00Z,,2013-08-11T03:12:26Z,,0,0,0900006480bc0e72
FDA-2010-N-0002-0089,FDA,FDA-2010-N-0002,Freedom of Information Summary - [NADA-141-319] - Deslorelin acetate Injection Horses/Estrous mares,Other,FOIS-Freedom of Information Summary (No Federal Register Publication),2010-12-28T05:00:00Z,2010,12,2010-12-28T05:00:00Z,,2010-12-28T16:01:31Z,,0,0,0900006480bc13dc
FDA-2010-N-0001-0162,FDA,FDA-2010-N-0001,Request for Nominations: Voting and Non-Voting Members of Public Advisory Committees or Panels,Notice,N-Notice,2010-12-28T05:00:00Z,2010,12,2010-12-28T05:00:00Z,,2010-12-28T16:28:32Z,2010-32624,0,0,0900006480bc1153
FDA-2010-N-0447-0003,FDA,FDA-2010-N-0447,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Third Party Review Program Under the Food and Drug Administration Modernization Act",Notice,N-Notice,2010-12-28T05:00:00Z,2010,12,2010-12-28T05:00:00Z,,2011-03-14T20:37:01Z,2010-32603,0,0,0900006480bc0c82
FDA-1997-N-0020-0013,FDA,FDA-1997-N-0020,Substances Generally Recognized as Safe; Reopening of the Comment,Proposed Rule,Reopening of Comment Period,2010-12-28T05:00:00Z,2010,12,2010-12-28T05:00:00Z,2011-03-29T03:59:59Z,2016-09-29T01:00:28Z,2010-32344,0,0,0900006480bc0c0f
FDA-2010-N-0511-0002,FDA,FDA-2010-N-0511,FDA/DDM Letter to Division of Wyeth Holdings - Letter,Other,,2010-12-28T00:00:00Z,2010,12,,,2010-12-29T14:18:57Z,,0,1,0900006480b77e4c
FDA-2010-N-0001-0160,FDA,FDA-2010-N-0001,Circulatory System Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting,Notice,NM-Notice of Meeting,2010-12-27T05:00:00Z,2010,12,2010-12-27T05:00:00Z,,2010-12-27T14:48:01Z,2010-32367,0,0,0900006480bc03c3
FDA-2010-P-0630-0009,FDA,FDA-2010-P-0630,"Acknowledgement Letter to Heyltex Corporation, HEYL Chemisch-Pharmazeutische Fabrik GmbH & Co. KG - Correction",Other,Correction(s),2010-12-27T05:00:00Z,2010,12,2010-12-27T05:00:00Z,,2012-05-09T22:38:35Z,,0,0,0900006480bbd326
FDA-2010-E-0037-0007,FDA,FDA-2010-E-0037,U.S. Patent & Trademark Office to FDA/CDER - Letter with enclosure,Other,LET-Letter,2010-12-27T05:00:00Z,2010,12,2010-12-27T05:00:00Z,,2013-07-27T23:40:38Z,,0,0,0900006480bc087d
FDA-2010-N-0001-0159,FDA,FDA-2010-N-0001,Oncologic Drugs Advisory Committee; Cancellation,Notice,N-Notice,2010-12-27T05:00:00Z,2010,12,2010-12-27T05:00:00Z,,2010-12-27T14:44:55Z,2010-32413,0,0,0900006480bc0306
FDA-2010-P-0630-0008,FDA,FDA-2010-P-0630,"Attachment XII - ""Jekat, F. et al. IPCS Evaluation of Antidotes for Poisoning by Metals and Metalloids - Heyltex Corporation - [HEYL Chemisch-pharmazeutische Fabrik GmbH & Co. KG - Citizen Petition]",Supporting & Related Material,CP-Citizen Petition (Supporting & Related Materials),2010-12-27T05:00:00Z,2010,12,,,2010-12-27T19:31:41Z,,0,0,0900006480bb3e08
FDA-2010-P-0628-0004,FDA,FDA-2010-P-0628,"Attachment I - ""Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations"" - Heyltex Corporation [Heyl Chemisch-pharmazeutische Fabrik GnbH & Co. KG - Citizen Petition]",Supporting & Related Material,CP-Citizen Petition (Supporting & Related Materials),2010-12-27T05:00:00Z,2010,12,,,2010-12-27T19:14:05Z,,0,0,0900006480bb2c17
FDA-2010-P-0630-0006,FDA,FDA-2010-P-0630,"Attachment VI - ""Development of biokinetic models for the description of the effect of DTPA with regard to the diagnostic and therapy of incorporation of plutonium and other transuranium elements"" - Heyltex Corporation - [HEYL Chemisch-pharmazeutische Fabrik GmbH & Co. KG - Citizen Petition]",Supporting & Related Material,CP-Citizen Petition (Supporting & Related Materials),2010-12-27T05:00:00Z,2010,12,,,2010-12-27T19:29:18Z,,0,0,0900006480bb3df7
FDA-2010-P-0628-0006,FDA,FDA-2010-P-0628,"Attachment V - Breustedt, B. et al, ""Development of biokinetic models for the description of the effect of DTPA with regard to the diagnostic and therapy of incorporation of plutonium and other transuranium elements"" - Heyltex Corporation [Heyl Chemisch-pharmazeutische Fabrik GnbH & Co. KG - Citizen Petition]",Supporting & Related Material,CP-Citizen Petition (Supporting & Related Materials),2010-12-27T05:00:00Z,2010,12,,,2010-12-27T19:18:35Z,,0,0,0900006480bb30db
FDA-2010-P-0628-0007,FDA,FDA-2010-P-0628,"Attachment VII - ""Mayak Worker Study Project 2.4 Volume III Internal Dosimetry Dose Reconstruction Methods Used in Preparation of Doses-2005 Database"" - Heyltex Corporation [Heyl Chemisch-pharmazeutische Fabrik GnbH & Co. KG - Citizen Petition]",Supporting & Related Material,CP-Citizen Petition (Supporting & Related Materials),2010-12-27T05:00:00Z,2010,12,,,2010-12-27T19:19:56Z,,0,0,0900006480bb30de
FDA-2009-E-0020-0009,FDA,FDA-2009-E-0020,"U.S. Patent & Trademark Office to  Millen, White, Zelano & Branigan, P.C. - Notice of Final Determinaton",Other,LET-Letter,2010-12-27T05:00:00Z,2010,12,2010-12-27T05:00:00Z,,2013-08-11T03:12:25Z,,0,0,0900006480bc0880
FDA-2004-E-0266-0009,FDA,FDA-2004-E-0266,U.S. Patent & Trademark Office to  Connolly Bove Lodge & Hutz LLP - Notice of Final Determinaton,Other,LET-Letter,2010-12-27T05:00:00Z,2010,12,2010-12-27T05:00:00Z,,2013-07-27T23:40:38Z,,0,0,0900006480bc087f
FDA-2010-P-0582-0005,FDA,FDA-2010-P-0582,"Acknowledgement Letter to Lachman Consultant Services, Inc.",Other,ACK-Acknowledgement Letter,2010-12-27T05:00:00Z,2010,12,2010-12-27T05:00:00Z,,2013-07-27T23:37:21Z,,0,0,0900006480b8a212
FDA-2010-P-0582-0003,FDA,FDA-2010-P-0582,"Attachment 2 - ""Description Information, Mercaptopurine Tablets, USP"" - [Lachman Consultant Services, Inc. - Citizen Petition]",Supporting & Related Material,CP-Citizen Petition (Supporting & Related Materials),2010-12-27T05:00:00Z,2010,12,,,2010-12-27T18:31:36Z,,0,0,0900006480b8a0c0
FDA-2010-P-0628-0005,FDA,FDA-2010-P-0628,"Attachment II - ""Federal Register/ Vol. 68, No. 178/ Monday, September 15, 2003/Notice"" - Heyltex Corporation [Heyl Chemisch-pharmazeutische Fabrik GnbH & Co. KG - Citizen Petition]",Supporting & Related Material,CP-Citizen Petition (Supporting & Related Materials),2010-12-27T05:00:00Z,2010,12,,,2010-12-27T19:16:46Z,,0,0,0900006480bb2c18
FDA-2007-E-0048-0008,FDA,FDA-2007-E-0048,"U.S. Patent & Trademark Office to Harness, Dickey & Pierce, PLC  - Notice of Final Determinaton",Other,LET-Letter,2010-12-27T05:00:00Z,2010,12,2010-12-27T05:00:00Z,,2013-08-11T01:38:57Z,,0,0,0900006480bc0881
FDA-2010-P-0628-0008,FDA,FDA-2010-P-0628,"Attachment XI - ""IPCS Evaluation of Antidotes for Poisoning by Metals and Metalloids"" Heyltex Corporation [Heyl Chemisch-pharmazeutische Fabrik GnbH & Co. KG - Citizen Petition]",Supporting & Related Material,CP-Citizen Petition (Supporting & Related Materials),2010-12-27T05:00:00Z,2010,12,,,2010-12-27T19:36:22Z,,0,0,0900006480bb30e2
FDA-2010-P-0582-0002,FDA,FDA-2010-P-0582,"Attachment 1 ""Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations"" - [Lachman Consultant Services, Inc. - Citizen Petition]",Supporting & Related Material,CP-Citizen Petition (Supporting & Related Materials),2010-12-27T05:00:00Z,2010,12,,,2010-12-27T18:31:35Z,,0,0,0900006480b8a0bf
FDA-2010-P-0582-0004,FDA,FDA-2010-P-0582,"Attachment 3 - ""Description Information, Purinethol - Mercaptopurine Tablets, Gate Pharmaceuticals"" - [Lachman Consultant Services, Inc. - Citizen Petition]",Supporting & Related Material,CP-Citizen Petition (Supporting & Related Materials),2010-12-27T05:00:00Z,2010,12,,,2010-12-27T18:31:38Z,,0,0,0900006480b8a15d
FDA-2010-V-0587-0002,FDA,FDA-2010-V-0587,Acknowledgement Letter to Syndicate Hospitality Group,Other,ACK-Acknowledgement Letter,2010-12-27T05:00:00Z,2010,12,2010-12-27T05:00:00Z,,2013-07-27T23:37:31Z,,0,0,0900006480b93263